TearLab Corporation (NASDAQ:TEAR) is scheduled to release its earnings data after the market closes on Monday, August 14th. Analysts expect TearLab Corporation to post earnings of ($0.75) per share for the quarter.
TearLab Corporation (NASDAQ:TEAR) last issued its quarterly earnings results on Monday, May 15th. The medical research company reported ($0.82) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.75) by $0.07. The company had revenue of $6.70 million during the quarter, compared to analyst estimates of $7.02 million. The company’s revenue for the quarter was down 1.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.21) EPS. On average, analysts expect TearLab Corporation to post $-2.82 EPS for the current fiscal year and $-1.39 EPS for the next fiscal year.
Shares of TearLab Corporation (NASDAQ TEAR) opened at 2.01 on Friday. TearLab Corporation has a one year low of $1.55 and a one year high of $8.20. The company’s market capitalization is $11.53 million. The company’s 50-day moving average price is $2.09 and its 200-day moving average price is $2.98.
Several analysts have commented on the company. HC Wainwright reiterated a “buy” rating and set a $4.00 target price on shares of TearLab Corporation in a research note on Tuesday, May 16th. Rodman & Renshaw cut their target price on TearLab Corporation from $12.00 to $4.00 and set a “buy” rating on the stock in a research note on Tuesday, May 16th. Finally, Zacks Investment Research downgraded TearLab Corporation from a “buy” rating to a “hold” rating in a research note on Tuesday, May 16th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $5.05.
TRADEMARK VIOLATION WARNING: This story was reported by Transcript Daily and is owned by of Transcript Daily. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this story can be accessed at https://transcriptdaily.com/2017/08/13/tearlab-corporation-nasdaqtear-set-to-announce-quarterly-earnings-on-monday.html.
TearLab Corporation Company Profile
TearLab Corporation is an in-vitro diagnostic company. The Company has commercialized a tear testing platform, the TearLab Osmolarity System, which enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company, through its subsidiary TearLab Research, Inc, develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites, genes and proteins) at the point-of-care.
Receive News & Ratings for TearLab Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TearLab Corporation and related companies with MarketBeat.com's FREE daily email newsletter.